Tags

Type your tag names separated by a space and hit enter

Oral supplementation of lutein/zeaxanthin and omega-3 long chain polyunsaturated fatty acids in persons aged 60 years or older, with or without AMD.
Invest Ophthalmol Vis Sci. 2008 Sep; 49(9):3864-9.IO

Abstract

PURPOSE

Increased dietary intake of lutein/zeaxanthin and omega-long-chain polyunsaturated fatty acids (omega-3 LCPUFA) was found to be associated with reduced risk of advanced age-related macular degeneration (AMD). The purpose of the study was to examine the effect of oral supplementation of omega-3 LCPUFA on changes in serum levels of lutein/zeaxanthin during supplementation in persons 60 years of age and older, with or without AMD.

METHODS

Forty participants with AMD of various degrees of severity received lutein (10 mg) and zeaxanthin (2 mg) daily and were equally randomized to receive omega-3 LCPUFA (350 mg docosahexaenoic acid [DHA] and 650 mg eicosapentaenoic acid [EPA]) or placebo for 6 months. Serum levels of lutein, zeaxanthin, and omega-3 LCPUFAs and macular pigment optical densities were measured at baseline, 1 week, and 1, 3, 6, and 9 months.

RESULTS

By month 6, the median serum levels of lutein/zeaxanthin increased by two- to threefold compared with baseline. Increases in serum levels of lutein/zeaxanthin did not differ by omega-3 LCPUFA treatment (P > 0.5). After 1 month, in the omega-3 LCPUFA-treated group, the median levels of DHA and EPA increased and the placebo group had no changes. At month 6, participants with AMD had a lower increase in serum lutein concentration than did those without AMD (P < 0.05).

CONCLUSIONS

The addition of omega-3 LCPUFA to oral supplementation of lutein/zeaxanthin did not change the serum levels of lutein and zeaxanthin. A long-term large clinical trial is necessary to investigate the benefits and adverse effects of these factors for the treatment of AMD.

Authors+Show Affiliations

Clinical Trials Branch, Division of Epidemiology and Clinical Research, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18450596

Citation

Huang, Lynn L., et al. "Oral Supplementation of Lutein/zeaxanthin and Omega-3 Long Chain Polyunsaturated Fatty Acids in Persons Aged 60 Years or Older, With or Without AMD." Investigative Ophthalmology & Visual Science, vol. 49, no. 9, 2008, pp. 3864-9.
Huang LL, Coleman HR, Kim J, et al. Oral supplementation of lutein/zeaxanthin and omega-3 long chain polyunsaturated fatty acids in persons aged 60 years or older, with or without AMD. Invest Ophthalmol Vis Sci. 2008;49(9):3864-9.
Huang, L. L., Coleman, H. R., Kim, J., de Monasterio, F., Wong, W. T., Schleicher, R. L., Ferris, F. L., & Chew, E. Y. (2008). Oral supplementation of lutein/zeaxanthin and omega-3 long chain polyunsaturated fatty acids in persons aged 60 years or older, with or without AMD. Investigative Ophthalmology & Visual Science, 49(9), 3864-9. https://doi.org/10.1167/iovs.07-1420
Huang LL, et al. Oral Supplementation of Lutein/zeaxanthin and Omega-3 Long Chain Polyunsaturated Fatty Acids in Persons Aged 60 Years or Older, With or Without AMD. Invest Ophthalmol Vis Sci. 2008;49(9):3864-9. PubMed PMID: 18450596.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral supplementation of lutein/zeaxanthin and omega-3 long chain polyunsaturated fatty acids in persons aged 60 years or older, with or without AMD. AU - Huang,Lynn L, AU - Coleman,Hanna R, AU - Kim,Jonghyeon, AU - de Monasterio,Francisco, AU - Wong,Wai T, AU - Schleicher,Rosemary L, AU - Ferris,Frederick L,3rd AU - Chew,Emily Y, Y1 - 2008/04/30/ PY - 2008/5/3/pubmed PY - 2008/10/7/medline PY - 2008/5/3/entrez SP - 3864 EP - 9 JF - Investigative ophthalmology & visual science JO - Invest. Ophthalmol. Vis. Sci. VL - 49 IS - 9 N2 - PURPOSE: Increased dietary intake of lutein/zeaxanthin and omega-long-chain polyunsaturated fatty acids (omega-3 LCPUFA) was found to be associated with reduced risk of advanced age-related macular degeneration (AMD). The purpose of the study was to examine the effect of oral supplementation of omega-3 LCPUFA on changes in serum levels of lutein/zeaxanthin during supplementation in persons 60 years of age and older, with or without AMD. METHODS: Forty participants with AMD of various degrees of severity received lutein (10 mg) and zeaxanthin (2 mg) daily and were equally randomized to receive omega-3 LCPUFA (350 mg docosahexaenoic acid [DHA] and 650 mg eicosapentaenoic acid [EPA]) or placebo for 6 months. Serum levels of lutein, zeaxanthin, and omega-3 LCPUFAs and macular pigment optical densities were measured at baseline, 1 week, and 1, 3, 6, and 9 months. RESULTS: By month 6, the median serum levels of lutein/zeaxanthin increased by two- to threefold compared with baseline. Increases in serum levels of lutein/zeaxanthin did not differ by omega-3 LCPUFA treatment (P > 0.5). After 1 month, in the omega-3 LCPUFA-treated group, the median levels of DHA and EPA increased and the placebo group had no changes. At month 6, participants with AMD had a lower increase in serum lutein concentration than did those without AMD (P < 0.05). CONCLUSIONS: The addition of omega-3 LCPUFA to oral supplementation of lutein/zeaxanthin did not change the serum levels of lutein and zeaxanthin. A long-term large clinical trial is necessary to investigate the benefits and adverse effects of these factors for the treatment of AMD. SN - 1552-5783 UR - https://www.unboundmedicine.com/medline/citation/18450596/Oral_supplementation_of_lutein/zeaxanthin_and_omega_3_long_chain_polyunsaturated_fatty_acids_in_persons_aged_60_years_or_older_with_or_without_AMD_ L2 - http://iovs.arvojournals.org/article.aspx?doi=10.1167/iovs.07-1420 DB - PRIME DP - Unbound Medicine ER -